Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406366 | 0.85 | PARP1 (0.62) | PARP1KCNH2PARP2TNK1TNK2 | |
| Hydrochloric Acid SCHEMBL6406238 | 0.84 | PARP1 (0.76) | PARP1KCNH2PARP2MEN1KMT2A | |
| SCHEMBL3392726 | 0.76 | ALDH1A1 (0.50) | KCNH2MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL6403678 | 0.75 | PARP1 (0.55) | PARP1KCNH2PARP2 | |
| SCHEMBL25821683 | 0.75 | PARP1 (0.69) | PARP1KCNH2PARP2TNK1 | |
| Hydrochloric Acid SCHEMBL6404123 | 0.72 | PARP1 (0.98) | PARP1KCNH2PARP2MEN1KMT2A | |
| SCHEMBL13070096 | 0.72 | ALDH1A1 (0.42) | PARP1MEN1KMT2A | |
| SCHEMBL6374877 | 0.71 | PARP1 (0.71) | PARP1KCNH2PARP2 | |
| Hydrochloric Acid SCHEMBL6404102 | 0.71 | PARP1 (0.84) | PARP1KCNH2PARP2MEN1KMT2A | |
| SCHEMBL3392239 | 0.71 | ALDH1A1 (0.47) | KCNH2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | PARP1 1/4885KCNH2 2357/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.